Detalles de la búsqueda
1.
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Nature
; 629(8014): 1142-1148, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38588696
2.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Lancet
; 393(10191): 2599-2612, 2019 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31178152
3.
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
BMC Cancer
; 18(1): 391, 2018 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29621991
4.
Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.
Mod Pathol
; 30(8): 1069-1077, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28548129
5.
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Breast Cancer Res
; 18(1): 21, 2016 Feb 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-26882907
6.
Trastuzumab-associated cardiac events in the Persephone trial.
Br J Cancer
; 115(12): 1462-1470, 2016 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27875516
7.
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 16(6): 656-66, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25975632
8.
A Bayesian adaptive design for biomarker trials with linked treatments.
Br J Cancer
; 113(5): 699-705, 2015 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26263479
9.
Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?
BMC Med
; 13: 234, 2015 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26391216
10.
A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
BMC Med
; 13: 306, 2015 Dec 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-26715442
11.
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
Lancet Oncol
; 15(2): 201-12, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24360787
12.
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Health Technol Assess
; 24(40): 1-190, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32880572
13.
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
Clin Cancer Res
; 25(22): 6598-6605, 2019 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31439579
14.
The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study.
PLoS One
; 11(7): e0158984, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27392074
15.
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Clin Cancer Res
; 20(9): 2466-75, 2014 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24599932
Resultados
1 -
15
de 15
1
Próxima >
>>